Neuroendocrine Tumors Clinical Trials
7 recruiting trials for Neuroendocrine Tumors. Eligibility criteria explained in plain English.
TrialFinderData lists 7 Neuroendocrine Tumors clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Across the trials that carry a phase, Phase 2 is the largest group at 50% (2 studies); the largest phase groups are Phase 2: 2, Phase 3: 1, Phase 1 / Phase 2: 1.
Research is led by Australasian Gastro-Intestinal Trials Group (1), RayzeBio, Inc. (1), University of Florida (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Cessation of somatostatin analogues (drug, 1 trial), followed by Continuation of somatostatin analogues, RYZ101.
Track Neuroendocrine Tumors trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours
Neuroendocrine tumours (NETs) are slow growing cancers, which commonly present as metastatic incurable disease. Some neuroendocrine tumours, termed functional NETs, overproduce...
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following...
This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with...
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
Checkpoint inhibitor therapy represents a significant advance in cancer care. The interaction between PD-1 and PD-L1 induces immune tolerance, and the inhibition of this...
Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department
Development of a clinico-biological database allowing the provision of clinical data and corresponding biological materials to the medical and scientific community.
Observational Study on GEP-and Pulm-NET Treated at FPG
Observational ambispective monocentric study on the clinical, laboratory, pathological and molecular characteristics of patients suffering from gastroenteropancreatic tract and...
Agnostic Therapy in Rare Solid Tumors
The ANTARES study is a phase II basket trial designed to evaluate the tissue-agnostic efficacy of the monoclonal anti-PD1 antibody, nivolumab, in patients with advanced or...
Integrated Cancer Repository for Cancer Research
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal...
Explore Other Conditions
Frequently Asked Questions
There are currently 7 clinical trials for Neuroendocrine Tumors, with 7 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Neuroendocrine Tumors, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 1 Phase 3 trials for Neuroendocrine Tumors, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.